ER Positive Breast Cancer Clinical Trials

7 recruiting

ER Positive Breast Cancer Trials at a Glance

7 actively recruiting trials for er positive breast cancer are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Chicago, Cluj-Napoca, and Adelaide. Lead sponsors running er positive breast cancer studies include Olema Pharmaceuticals, Inc., Abramson Cancer Center at Penn Medicine, and Fondazione Sandro Pitigliani.

Browse er positive breast cancer trials by phase

Treatments under study

About ER Positive Breast Cancer Clinical Trials

Looking for clinical trials for ER Positive Breast Cancer? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ER Positive Breast Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ER Positive Breast Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerER Positive Breast Cancer+1 more
Olema Pharmaceuticals, Inc.1,000 enrolled85 locationsNCT07085767
Recruiting
Phase 2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Breast CancerER Positive Breast CancerHER2-positive Breast Cancer+1 more
Ruth O'Regan30 enrolled4 locationsNCT04886531
Recruiting
Phase 3

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Phase 2

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Breast CancerBreast Cancer FemaleHER2-negative Breast Cancer+2 more
Sarah Sammons, MD58 enrolled3 locationsNCT06176261
Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

Breast CancerHER2-negative Breast CancerER Positive Breast Cancer+1 more
Abramson Cancer Center at Penn Medicine300 enrolled1 locationNCT05396612
Recruiting

To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

Metastatic Breast CancerHER2-negative Breast CancerER Positive Breast Cancer
Fondazione Sandro Pitigliani150 enrolled1 locationNCT04660435
Recruiting
Phase 2

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Metastatic Breast CancerER Positive Breast CancerPremenopausal Breast Cancer
National Taiwan University Hospital42 enrolled1 locationNCT05720260